Engineering sterile systems that remain compliant, reliable, and inspection-ready across their entire lifecycle.
In sterile manufacturing, the consequences of an equipment design decision rarely end at installation. They surface years later during inspections, expansions, remediation exercises, and moments when systems are pushed beyond their original assumptions.
For this edition of the Hello Pharma Startup Series, we speak with Madhumeeta Kumari and Shishir Mishra, the founding partners of Esteril Process Solutions. With more than two and a half decades of combined experience across pharmaceutical machinery, turnkey execution, aseptic operations, and regulatory audits, their entrepreneurial journey emerged not from a gap in the market, but from a gap in thinking.
Having witnessed firsthand how short-term engineering choices often translate into long-term compliance and operational risk, they set out to build sterile processing systems anchored in lifecycle reliability, validation clarity, and regulatory foresight. This conversation explores the technical inflection points that led to Esteril’s formation, the compromises the industry has quietly normalized, and how disciplined engineering can reshape the future of sterile manufacturing.
Most technology-driven companies are born out of a very specific technical inflection point. Was there a particular project, audit observation, or validation challenge that made you realize existing sterile processing solutions were no longer adequate and that Esteril needed to be built?
We both started our careers in the same industry, and together we bring over 25 years of combined experience in pharmaceutical machinery and turnkey projects. Over this journey, we have seen sterile manufacturing from every angle, on the shop floor, during commissioning, and through regulatory audits. These experiences have strongly shaped how we think about quality and engineering.
One realization stayed with us throughout. In injectable facilities, choosing an equipment partner is not just a commercial decision. It is a long-term quality decision. While the industry has many capable suppliers, we often felt that solutions were designed to address immediate project needs, without always keeping future regulations and long-term reliability in mind.
Over time, this understanding turned into a clear vision. To build equipment that does not just meet today’s requirements, but remains compliant, robust, and dependable throughout its entire lifecycle. That belief, built through years of hands-on experience, became the foundation on which Esteril was created.
Prior to starting Esteril, you would have had direct exposure to aseptic operations, cleanroom behavior, and regulatory expectations. Which recurring technical or compliance gaps did you observe in sterile processing that were being normalized by the industry but needed a fundamental rethink?
Through sustained exposure to aseptic operations and evolving regulatory expectations, we consistently observed that automation remained a sensitive and complex area. While automation solutions were available and functional, achieving truly seamless, end-to-end integration across processes, along with long-term ease of operation and maintenance, was often challenging. Over time, many of these limitations became accepted as normal operational realities within sterile manufacturing environments.
We viewed this not as a fault of existing practices, but as a natural outcome of rapidly evolving regulatory and technological demands. This perspective encouraged us to rethink how automation could be designed and delivered, with greater simplicity, better integration, and stronger alignment with validation and compliance needs. Our focus was to make automation more intuitive, dependable, and supportive of day-to-day operations, thereby reducing complexity while enhancing overall process reliability and regulatory confidence.
When you defined Esteril’s initial problem statement, what was the core technical risk you wanted to eliminate first? Was it contamination control, process repeatability, validation complexity, operator dependency, or lifecycle compliance?
When we defined Esteril’s initial problem statement, our primary focus was on reducing validation complexity. Over the years, we had observed that many compliance challenges, and even regulatory observations including FDA warnings, often originated from systems that were difficult to validate and sustain over their lifecycle.
This challenge was closely linked to operator dependency. As long as critical processes rely heavily on manual intervention, there is an inherent risk of variability and unintentional error at different stages of operation. Human involvement is essential, but excessive dependence increases the likelihood of deviations, especially in sterile environments where precision is critical.
We believed that by strengthening automation and embedding controls at the system level, many of these risks could be mitigated. When automation performs repetitive and critical tasks consistently, it becomes easier to manage processes, handle deviations, and maintain compliance. Our intent was not to replace people, but to support them with systems that simplify validation, improve repeatability, and enhance overall process reliability throughout the equipment lifecycle.
Esteril’s foundation reflects a convergence of varied technical strengths. How did expertise across process engineering, automation, quality systems, and regulatory compliance come together to influence your early system architecture and design philosophy?
Esteril’s foundation was built on the collective experience of a core team drawn from different parts of the pharmaceutical engineering ecosystem. Our leadership across design, production, quality, and compliance brings decades of hands-on industry exposure, allowing us to view system design from multiple practical and regulatory perspectives.
From the very beginning, our system architecture and design philosophy were clearly defined. It had to be customer-centric. Every decision, whether related to process engineering, automation logic, or quality documentation, was evaluated through the lens of the customer’s operational needs, regulatory responsibilities, and long-term usability.
This convergence of expertise helped us create systems that are not only technically sound, but also practical to operate, validate, and maintain. By keeping the customer’s interest at the center, we ensured that engineering excellence, compliance readiness, and ease of use evolved together rather than in isolation.
Early-stage engineering companies often face a trade-off between speed and robustness. What were the biggest technical or validation-related hurdles during the initial phase, and how did you ensure design integrity while still moving fast?
Like most early-stage engineering companies, we did face challenges during the initial phase. However, given the critical nature of the pharmaceutical industry, compromising on either speed or robustness was never an option for us. Both are equally essential to meet project timelines while ensuring compliance and system reliability.
One of the key hurdles we encountered was building the right manpower structure to support this balance. Sterile engineering demands specialized skills across design, execution, documentation, and validation, and aligning these resources early on was a challenge.
Today, we operate with a focused in-house team of around 25 professionals, supported by more than 15 experienced contract resources. This hybrid model allows us to scale quickly while maintaining quality, design integrity, and validation rigor. By clearly defining roles, processes, and review mechanisms, we were able to move efficiently without compromising the robustness expected in regulated environments.
When developing your first sterile processing solutions, certain design principles become non-negotiable. What were the must-have elements in terms of material selection, surface finishes, cleanability, automation logic, and GMP compliance that guided every design decision?
To be honest, when we started designing our first sterile processing solutions, we knew there was no room for compromise. In sterile manufacturing, even small design misses can create big problems, so we treated every element as non-negotiable from day one.
Our biggest focus was always on getting better product yield and reducing turnaround time during cleaning and sterilisation. That goal influenced almost every design decision we made. We paid close attention to material selection, hygienic piping layouts, and surface finishes that make cleaning effective and repeatable, while also reducing hold-up volumes and dead legs.
At the same time, we built automation logic that’s robust but practical—something that operators can rely on day after day, with minimal manual intervention and consistent CIP/SIP performance. And of course, everything was designed with strict alignment to GMP and FDA expectations, not just to clear audits, but to ensure long-term reliability and process consistency.
In the end, our design philosophy was simple; equipment should not only meet today’s requirements, but continue performing reliably over its entire lifecycle, without compromising sterility, efficiency, or compliance.
Building a global-quality sterile processing brand requires alignment with evolving international regulations. How do you interpret “global quality” in practical terms when designing systems to meet US FDA, EU GMP, and other regulatory expectations?
For us, global quality means designing equipment that meets international regulatory expectations from the very beginning, rather than making changes later to satisfy audits. Whether it is US FDA, EU GMP, or other global regulations, the fundamental expectations remain consistent. Patient safety, process consistency, equipment reliability, and cleanability by design.
In practical terms, this means our systems are designed with the right materials, hygienic and drainable layouts, appropriate surface finishes, and automation that supports controlled and repeatable operation. Equipment must be easy to clean, easy to sterilize, and easy to validate, with clear and logical documentation to support regulatory inspections.
We closely track regulatory guidance and inspection observations related to equipment design and sterile manufacturing, and we continuously strengthen our engineering and documentation practices accordingly. Our focus is to keep systems robust, simple, and inspection-ready, so compliance becomes a natural outcome of good equipment design.
Sustaining technical excellence requires more than good equipment. What internal systems, training frameworks, and quality culture have you put in place to ensure consistency as Esteril scales?
Sustaining technical excellence requires more than good equipment. It depends on strong systems, continuous learning, and the right quality mindset. At Esteril, we are still evolving and strengthening our internal processes as we grow, with a clear focus on making them more robust and aligned with global regulatory expectations.
We are gradually implementing standardized engineering and documentation practices that align with EU GMP and US FDA norms, so that regulatory requirements are built into our design and execution processes from the beginning. Regular cross-functional reviews between engineering, quality, automation, and production help us identify gaps early and improve consistency.
Most importantly, we are building a quality culture that encourages learning, ownership, and continuous improvement. We believe that strong systems take time to mature, and we are consciously investing in people, processes, and training to ensure that as Esteril scales, our engineering, documentation, and execution remain consistent, compliant, and reliable.
The sterile processing space is evolving rapidly. Which technological shifts will have the most impact, and how is Esteril preparing for future regulatory and manufacturing paradigms?
The sterile processing industry is changing quickly due to higher levels of automation, digital monitoring, and stricter sterility requirements. Whether we call it Pharma 4.0 or Pharma 5.0, the core idea remains the same. Using data and technology to make processes more reliable and less dependent on manual intervention.
We see strong potential in using data from activities such as CIP and SIP cycles, mixing operations, and process trends to better define how a process should run. For example, data can help determine the right agitator speed, correct mixing time, or whether cleaning has been effective. Over time, technologies such as analytics and AI can support more consistent and controlled manufacturing.
At Esteril, we are gradually preparing our systems to support these technologies. Our focus is on designing equipment that is automation-ready, capable of capturing process data, and flexible enough to adopt future upgrades. We see this as a step-by-step journey, where technology adoption goes hand in hand with regulatory acceptance and practical use on the shop floor.
Disclaimer
The views and opinions expressed in this editorial are those of the interviewees and are based on their professional experience in pharmaceutical engineering and sterile manufacturing. They do not necessarily reflect the official views, policies, or positions of Hello Pharma, its management, or its affiliates. Hello Pharma does not endorse or take responsibility for any specific technical, commercial, or regulatory interpretations presented in this article. Readers are encouraged to independently evaluate the information shared, review applicable regulatory guidance, and rely on their own experience, expertise, and professional judgment before making decisions related to equipment selection, system design, validation strategy, or regulatory compliance.
About Hello Pharma StartUp Series
At Hello Pharma, we believe that some of the most meaningful innovation in the pharmaceutical sector is coming from founders who are building with depth, intent, and real shop-floor understanding. Through the #HelloPharmaStartUpSeries, we actively spotlight credible, engineering-led pharma startups and share their journeys, thinking, and solutions with the wider industry.
If you have founded or co-own a pharmaceutical startup in the last five years (post-2021) and believe your work brings genuine value to the ecosystem, we would love to hear from you. Write to us at getstarted@hello-pharma.com, and our editorial team will get in touch to understand your story, assess fit, and explore featuring you in an upcoming edition of the Hello Pharma StartUp Series.
